Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
NEW YORK, May 07, 2018 -- Safirstein Metcalf LLP and HGT Law remind investors that a shareholder “opt-out” lawsuit (“Lawsuit”) has been filed on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) and its senior officers for violations of federal securities laws and invite investors to contact the firms.
Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant (“Class Action”). More than twenty lawsuits have been filed on behalf of institutional investors who have decided to opt out of the Class Action to directly pursue their own claims. To date, the Lawsuit commenced by Safirstein Metcalf LLP and HGT Law is the only opt-out lawsuit that has been filed on behalf of retail investors.
A copy of the complaint filed by Safirstein Metcalf LLP and HGT Law on behalf of the Investors can be found here. For more information on opt-out lawsuits, see our publication here.
If you purchased Valeant common stock during the period from January 4, 2013 through March 15, 2016 and suffered losses of more than $200,000, then you may wish to consider opting out of the existing class action and joining the Lawsuit. A number of large institutional investors such as T. Rowe Price, Blackrock and Prudential Insurance Company have already opted out of the class action. If you would like to learn about the options available to you, please call 1-800-221-0015, email [email protected] or visit www.valeantshareholderlitigation.com
Company: Valeant Pharmaceuticals International, Inc.
Exchange: NYSE
Ticker: VRX
Class Period: 01/04/2013 – 03/15/2016
About Safirstein Metcalf LLP and HGT Law
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
HGT Law is a boutique commercial litigation firm based in New York. The firm focuses on representing investors in securities litigation and corporate governance/derivative litigation.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
Safirstein Metcalf LLP
The Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
